Aarti Pharmalabs Share Price
990.70+0.00 (-3.31%)
+42.75% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
LAURUSLABSNSE
ZYDUSLIFENSE
DRREDDYNSE
CIPLANSE
MANKINDNSE
AUROPHARMANSE
LUPINNSE
AARTIPHARMNSE
Aarti Pharmalabs Share Price
990.70+0.00 (-3.31%)
+42.75% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| - | - | -2% | -14% |
| - | - | -3% | -36% |
| - | - | 36% | 43% |
| 11% | 14% | 12% | 9% |
Peer Comparison
Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
LAURUSLABS
ZYDUSLIFE
DRREDDY
CIPLA
MANKIND
AUROPHARMA
LUPIN
AARTIPHARM
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 1,908.7 | ₹456593 Cr | 41.64 | 8.29 | 58.23 | ₹11479 Cr |
| 11,120.5 | ₹296741 Cr | 88.24 | 42.53 | 146.01 | ₹2568 Cr |
| 4,626.2 | ₹175578 Cr | 82.66 | 14.04 | 106.21 | ₹2163 Cr |
| 2,304.4 | ₹124380 Cr | 92.83 | 8.17 | 33.94 | ₹889 Cr |
| 1,235 | ₹119700 Cr | 28.64 | 9.27 | 62.23 | ₹5040 Cr |
| 1,396.5 | ₹116771 Cr | 41.71 | 11.08 | 59.16 | ₹4196 Cr |
| 1,421.8 | ₹114397 Cr | 39.49 | 10.86 | 52.6 | ₹3879 Cr |
| 2,636.7 | ₹108641 Cr | 48.44 | 17.23 | 76.25 | ₹1913 Cr |
| 1,803.3 | ₹103971 Cr | 26.06 | 19.57 | 103.44 | ₹3505 Cr |
| 2,002.6 | ₹91413 Cr | 17.56 | 25.26 | 150.99 | ₹5333 Cr |
| 1,013.6 | ₹9293 Cr | 36.2 | 7.88 | 41.25 | ₹175 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹610 Cr | ₹536 Cr | ₹583 Cr | ₹432 Cr | ₹418 Cr | ₹386 Cr | ₹564 Cr | ₹538 Cr | ₹458 Cr | ₹555 Cr | ₹506 Cr | ₹449 Cr | ₹440 Cr | ₹458 Cr | ₹485 Cr | ₹472 Cr | ₹531 Cr | ₹457 Cr | ₹460 Cr |
| ₹47 L | ₹45 L | ₹8 Cr | -₹37 L | ₹48 L | ₹77 L | ₹86 L | ₹5 Cr | ₹4 Cr | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹99 L | ₹48 L | ₹74 L | ₹29 L | ₹1 Cr | ₹2 L | ₹3 Cr |
| ₹611 Cr | ₹536 Cr | ₹591 Cr | ₹432 Cr | ₹419 Cr | ₹387 Cr | ₹565 Cr | ₹543 Cr | ₹463 Cr | ₹558 Cr | ₹508 Cr | ₹450 Cr | ₹441 Cr | ₹459 Cr | ₹486 Cr | ₹472 Cr | ₹532 Cr | ₹457 Cr | ₹463 Cr |
| ₹506 Cr | ₹430 Cr | ₹498 Cr | ₹359 Cr | ₹379 Cr | ₹318 Cr | ₹443 Cr | ₹432 Cr | ₹385 Cr | ₹479 Cr | ₹407 Cr | ₹372 Cr | ₹370 Cr | ₹391 Cr | ₹421 Cr | ₹402 Cr | ₹458 Cr | ₹385 Cr | ₹399 Cr |
| ₹136 Cr | ₹137 Cr | ₹121 Cr | ₹102 Cr | ₹65 Cr | ₹92 Cr | ₹144 Cr | ₹134 Cr | ₹98 Cr | ₹99 Cr | ₹120 Cr | ₹97 Cr | ₹89 Cr | ₹85 Cr | ₹81 Cr | ₹87 Cr | ₹91 Cr | ₹86 Cr | ₹78 Cr |
| ₹15 Cr | ₹13 Cr | ₹17 Cr | ₹13 Cr | ₹11 Cr | ₹7 Cr | ₹7 Cr | ₹10 Cr | ₹6 Cr | ₹5 Cr | ₹5 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹6 Cr | ₹5 Cr | ₹6 Cr | ₹4 Cr | ₹5 Cr |
| ₹88 Cr | ₹94 Cr | ₹76 Cr | ₹58 Cr | ₹29 Cr | ₹63 Cr | ₹115 Cr | ₹101 Cr | ₹72 Cr | ₹74 Cr | ₹96 Cr | ₹74 Cr | ₹67 Cr | ₹64 Cr | ₹59 Cr | ₹65 Cr | ₹69 Cr | ₹68 Cr | ₹59 Cr |
| ₹65 Cr | ₹69 Cr | ₹56 Cr | ₹43 Cr | ₹21 Cr | ₹48 Cr | ₹88 Cr | ₹74 Cr | ₹55 Cr | ₹55 Cr | ₹65 Cr | ₹53 Cr | ₹52 Cr | ₹47 Cr | ₹43 Cr | ₹48 Cr | ₹51 Cr | ₹52 Cr | ₹49 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Secured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
| — | — | — | — | — | — |
| ₹45 Cr | ₹45 Cr | ₹45 Cr | ₹45 Cr | ₹25 L | ₹25 L |
| ₹3 Cr | ₹2 Cr | ₹23 L | ₹0 | ₹45 Cr | ₹0 |
| ₹2076 Cr | ₹1943 Cr | ₹1712 Cr | ₹1513 Cr | ₹1341 Cr | -₹2 L |
| ₹2076 Cr | ₹1943 Cr | ₹1712 Cr | ₹1513 Cr | ₹1341 Cr | -₹2 L |
| ₹2125 Cr | ₹1990 Cr | ₹1757 Cr | ₹1558 Cr | ₹1386 Cr | ₹23 L |
| ₹186 Cr | ₹104 Cr | ₹4 L | ₹18 L | ₹55 L | ₹0 |
| ₹134 Cr | ₹128 Cr | ₹108 Cr | ₹79 Cr | ₹71 Cr | ₹0 |
| ₹92 Cr | ₹19 Cr | ₹17 Cr | ₹53 L | ₹2 Cr | ₹0 |
| ₹8 Cr | ₹8 Cr | ₹6 Cr | ₹5 Cr | ₹0 | ₹0 |
| ₹420 Cr | ₹259 Cr | ₹131 Cr | ₹85 Cr | ₹73 Cr | ₹0 |
| — | — | — | — | — | — |
| ₹335 Cr | ₹278 Cr | ₹378 Cr | ₹340 Cr | ₹215 Cr | ₹26,000 |
| ₹135 Cr | ₹70 Cr | ₹46 Cr | ₹38 Cr | ₹12 Cr | ₹20,000 |
| ₹457 Cr | ₹293 Cr | ₹264 Cr | ₹214 Cr | ₹338 Cr | ₹2 L |
| ₹11 Cr | ₹13 Cr | ₹6 Cr | ₹9 Cr | ₹16 Cr | ₹0 |
| ₹938 Cr | ₹653 Cr | ₹694 Cr | ₹601 Cr | ₹581 Cr | ₹2 L |
| ₹3482 Cr | ₹2902 Cr | ₹2582 Cr | ₹2244 Cr | ₹2040 Cr | ₹25 L |
| ₹8 Cr | ₹14 Cr | ₹7 Cr | ₹7 Cr | ₹0 | ₹0 |
| ₹686 Cr | ₹396 Cr | ₹264 Cr | ₹214 Cr | ₹339 Cr | ₹2 L |
| — | — | — | — | — | — |
| ₹2135 Cr | ₹1796 Cr | ₹1609 Cr | ₹1431 Cr | ₹1225 Cr | ₹0 |
| ₹697 Cr | ₹659 Cr | ₹576 Cr | ₹505 Cr | ₹443 Cr | ₹0 |
| ₹1437 Cr | ₹1137 Cr | ₹1033 Cr | ₹926 Cr | ₹782 Cr | ₹0 |
| ₹305 Cr | ₹307 Cr | ₹78 Cr | ₹62 Cr | ₹165 Cr | ₹0 |
| ₹194 Cr | ₹29 Cr | ₹37 Cr | ₹36 Cr | ₹32 Cr | ₹0 |
| ₹194 Cr | ₹29 Cr | ₹37 Cr | ₹36 Cr | ₹32 Cr | ₹0 |
| ₹60 Cr | ₹44 Cr | ₹29 Cr | ₹18 Cr | ₹10 Cr | ₹0 |
| ₹2084 Cr | ₹1584 Cr | ₹1236 Cr | ₹1081 Cr | ₹1012 Cr | ₹0 |
| — | — | — | — | — | — |
| ₹0 | ₹48 Cr | ₹70 Cr | ₹51 Cr | ₹0 | ₹0 |
| ₹640 Cr | ₹588 Cr | ₹643 Cr | ₹602 Cr | ₹475 Cr | ₹0 |
| ₹583 Cr | ₹575 Cr | ₹519 Cr | ₹450 Cr | ₹377 Cr | ₹0 |
| ₹10 Cr | ₹9 Cr | ₹24 Cr | ₹12 Cr | ₹83 Cr | ₹25 L |
| ₹12 Cr | ₹12 Cr | ₹17 Cr | ₹8 Cr | ₹11 Cr | ₹0 |
| ₹152 Cr | ₹87 Cr | ₹72 Cr | ₹40 Cr | ₹82 Cr | ₹0 |
| ₹1397 Cr | ₹1318 Cr | ₹1346 Cr | ₹1163 Cr | ₹1028 Cr | ₹25 L |
| ₹460 Cr | ₹665 Cr | ₹651 Cr | ₹562 Cr | ₹447 Cr | ₹23 L |
| ₹3482 Cr | ₹2902 Cr | ₹2582 Cr | ₹2244 Cr | ₹2040 Cr | ₹25 L |
| ₹234 | ₹219 | ₹194 | ₹172 | ₹53,647 | ₹9 |
| ₹234 | ₹219 | ₹194 | ₹172 | ₹53,647 | ₹9 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
| ₹228 Cr | ₹361 Cr | ₹300 Cr | ₹261 Cr | ₹155 Cr | -₹46,000 |
| ₹188 Cr | ₹120 Cr | ₹95 Cr | ₹83 Cr | ₹52 Cr | ₹0 |
| -₹107 Cr | -₹86 Cr | -₹122 Cr | -₹32 Cr | -₹230 Cr | ₹46,000 |
| ₹309 Cr | ₹395 Cr | ₹273 Cr | ₹312 Cr | -₹23 Cr | ₹0 |
| ₹262 Cr | ₹330 Cr | ₹216 Cr | ₹250 Cr | -₹44 Cr | ₹0 |
| -₹431 Cr | -₹412 Cr | -₹215 Cr | -₹158 Cr | -₹139 Cr | ₹0 |
| ₹171 Cr | ₹65 Cr | ₹10 Cr | -₹163 Cr | ₹260 Cr | ₹0 |
| ₹2 Cr | -₹17 Cr | ₹12 Cr | -₹71 Cr | ₹78 Cr | ₹0 |
| ₹7 Cr | ₹24 Cr | ₹12 Cr | ₹83 Cr | ₹5 Cr | ₹25 L |
| ₹9 Cr | ₹7 Cr | ₹24 Cr | ₹12 Cr | ₹83 Cr | ₹25 L |
Fundamental Ratios
Consolidated
Standalone

No results found
Aarti Pharmalabs Share Price
990.70+0.00 (-3.31%)
+42.75% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 5
Bearish signals: 1 out of 9 oscillators
RSI
59.62Buy
STOCH %K
62.86Neutral
MACD Level(12,26)
34.47Buy
Ultimate Oscillator
53.94Buy
Aroon Oscillator
84.00Buy
BOP
-0.68Sell
CCI
92.16Neutral
Williams %R
-37.14Neutral
Momentum
101.90Buy
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 9
Bearish signals: 0 out of 9 moving averages
EMA 9
986.94Buy
SMA 9
987.19Buy
EMA 21
951.58Buy
SMA 21
934.25Buy
EMA 50
906.01Buy
SMA 50
903.73Buy
EMA 200
812.81Buy
SMA 200
762.35Buy
WMA 20
967.29Buy
Pivot
Pivot
Classic
Resistance 5
1177.57
Resistance 4
1137.17
Resistance 3
1096.77
Resistance 2
1056.37
Resistance 1
1040.48
Pivot
1015.97
Support 1
1000.08
Support 2
975.57
Support 3
935.17
Support 4
894.77
Support 5
854.37
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Aarti Pharmalabs Share Price
990.70+0.00 (-3.31%)
+42.75% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| 39.66% | 42.86% | 43.08% | 43.10% | 42.88% | 43.72% |
| 8.16% | 8.17% | 8.39% | 7.68% | 8.02% | 7.34% |
| 7.80% | 6.42% | 6.60% | 6.57% | 6.16% | 6.90% |
| 0.60% | 0.79% | 0.80% | 1.09% | 0.79% | 0.90% |
| 43.78% | 41.76% | 41.13% | 41.56% | 42.15% | 41.14% |
Bulk & block deals
Name
Unifi Capital Private Limited
Jasmine Family Trust
Nk Securities Research Private Limited
Microcurves Trading Private Limited
Junomoneta Finsol Private Limited
Nk Securities Research Private Limited
Qe Securities Llp
Microcurves Trading Private Limited
Qe Securities Llp
Junomoneta Finsol Private Limited
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 21 Sep 2026 | Purchase | 75.03 Cr | ₹820 | 9.15 L | Bulk | 1.009045 | NSE |
| 18 Sep 2026 | Sell | 51.46 Cr | ₹820.02 | 6.28 L | Bulk | 0.691995 | NSE |
| 11 Aug 2026 | Sell | 57.90 Cr | ₹903.73 | 6.41 L | Bulk | 0.7065 | NSE |
| 11 Aug 2026 | Sell | 64.84 Cr | ₹904.35 | 7.17 L | Bulk | 0.790725 | NSE |
| 11 Aug 2026 | Sell | 41.10 Cr | ₹902.03 | 4.56 L | Bulk | 0.502494 | NSE |
| 11 Aug 2026 | Purchase | 57.85 Cr | ₹903.39 | 6.40 L | Bulk | 0.706239 | NSE |
| 11 Aug 2026 | Sell | 51.43 Cr | ₹902.18 | 5.70 L | Bulk | 0.628595 | NSE |
| 11 Aug 2026 | Purchase | 64.82 Cr | ₹903.94 | 7.17 L | Bulk | 0.790725 | NSE |
| 11 Aug 2026 | Purchase | 51.88 Cr | ₹899.52 | 5.77 L | Bulk | 0.636026 | NSE |
| 11 Aug 2026 | Purchase | 41.29 Cr | ₹901.69 | 4.58 L | Bulk | 0.505008 | NSE |
Insider trading & SAST
Client name
Gloire Trusteeship Services Private Limited
Rajendra Vallabhaji Gogri
Arti Rajendra Gogri
Relacion Trusteeship Services Private Limited
Relacion Trusteeship Services Private Limited
Gloire Trusteeship Services Private Limited
Safechem Enterprises Private Limited
Relacion Trusteeship Services Private Limited
Safechem Enterprises Private Limited
Safechem Enterprises Private Limited
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 25 Sep 2026 | Promoter Group | Disposal | 0.438356 | 0 | 32.55 Cr | ₹818.77 | 3.98 L | 21 Sep 2026 - 22 Sep 2026 | Market Sale | 0 | Insider Trading | — | Equity |
| 25 Sep 2026 | Promoter | Disposal | 0.428679 | 1.14 | 31.83 Cr | ₹818.77 | 3.89 L | 21 Sep 2026 - 22 Sep 2026 | Market Sale | 10,37,175 | Insider Trading | — | Equity |
| 25 Sep 2026 | Promoter Group | Disposal | 0.147292 | 0.35 | 10.94 Cr | ₹818.77 | 1.34 L | 21 Sep 2026 - 22 Sep 2026 | Market Sale | 3,21,692 | Insider Trading | — | Equity |
| 25 Sep 2026 | Promoter | Disposal | 0.419057 | 0 | 31.12 Cr | ₹818.83 | 3.80 L | 21 Sep 2026 - 22 Sep 2026 | Market Sale | 0 | Insider Trading | — | Equity |
| 22 Sep 2026 | Promoter Group | Disposal | 0.691995 | 0 | 51.38 Cr | ₹818.79 | 6.28 L | 18 Sep 2026 - 19 Sep 2026 | Market Sale | 0 | Insider Trading | — | Equity |
| 22 Sep 2026 | Promoter Group | Disposal | 0.688687 | 0 | 51.14 Cr | ₹818.83 | 6.25 L | 18 Sep 2026 - 19 Sep 2026 | Market Sale | 0 | Insider Trading | — | Equity |
| 09 Sep 2026 | Promoter Group | Disposal | 0.065505 | 0.4 | 5.20 Cr | ₹875.17 | 59.40 K | 07 Sep 2026 - 08 Sep 2026 | Market Sale | 3,65,750 | Insider Trading | — | Equity |
| 09 Sep 2026 | Promoter Group | Disposal | 0.066167 | 0.69 | 5.23 Cr | ₹871.08 | 60 K | 08 Sep 2026 - 09 Sep 2026 | Market Sale | 6,27,500 | Insider Trading | — | Equity |
| 07 Sep 2026 | Promoter Group | Disposal | 0.033083 | 0.47 | 2.59 Cr | ₹864.43 | 30 K | 04 Sep 2026 - 07 Sep 2026 | Market Sale | 4,25,150 | Insider Trading | — | Equity |
| 31 Aug 2026 | Promoter Group | Disposal | 0.000662 | 0.5 | 5.12 L | ₹853.15 | 600 | 26 Aug 2026 - 27 Aug 2026 | Market Sale | 4,55,150 | Insider Trading | — | Equity |
Aarti Pharmalabs Share Price
990.70+0.00 (-3.31%)
+42.75% past 1 Year
Aarti Pharmalabs Limited (APL) (Formerly known as Aarti Organics Limited) is a leading Indian manufacturer of Pharmaceuticals and Nutraceuticals with a global footprint. The company is an, internationally recognised manufacturer
Corporate Actions
Date
Type
Details
Company details
Aarti Pharmalabs Share Price
990.70+0.00 (-3.31%)
+42.75% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Aarti Pharmalabs Share Price
990.70+0.00 (-3.31%)
+42.75% past 1 Year
News
1 of 20
ResultAARTIPHARM28 Oct 2026
Aarti Pharmalabs reported second-quarter revenue from operations of Rs 610.00 crores, compared with Rs 418.00 crores in the corresponding quarter last year, representing year-on-year growth of approximately 46.0%. The reported result is consistent with the company’s September 2026 consolidated revenue from operations of Rs 610.45 crores.
EBITDA, PAT, operating margin, net margin, quarter-on-quarter performance, and market expectations were not provided in the available information and are therefore not included. The update indicates substantial annual revenue expansion for the quarter. Aarti Pharmalabs operates in the pharmaceuticals and bulk drugs industry, and its NSE symbol is AARTIPHARM.
Aarti Pharmalabs Reports Strong Second Quarter Consolidated Profit Growth
ResultAARTIPHARM28 Oct 2026
Aarti Pharmalabs reported consolidated Q2 net profit of Rs 75.40 crores, up 170.3 percent year on year from Rs 27.90 crores. Sequentially, profit declined 1.0 percent from Rs 76.14 crores in Q1 FY27. Revenue and EBITDA figures, operating margins, net margins, and street expectations were not provided in the available update. The result indicates a substantial year-on-year improvement in quarterly profitability, while the marginal sequential decline suggests broadly stable performance compared with the preceding quarter.
Block deal in Aarti Pharmalabs on NSE worth Rs 62.93 crores
Block DealAARTIPHARM18 Sept 2026
Aarti Pharmalabs witnessed a notable block deal on the NSE involving around 7.66 lakh shares, indicating meaningful institutional or large investor activity in the counter. The reported transaction size is approximately Rs 62.93 crores, with the shares exchanged at a price of Rs 821.9 per share. This kind of block trade typically reflects either portfolio rebalancing or strategic stake adjustment by large market participants, though the specific identities of the buyer and seller have not been disclosed in the available context. Based on the deal size, the transaction represents a sizable turnover for a single print and can draw short-term trading interest, especially from market participants tracking bulk and block deals for signals of changing ownership patterns.
At the reported deal price of Rs 821.9, the block trade may have been executed at a small discount or premium to the prevailing market price at the time, but the exact spread versus the live market quote is not specified in the provided information, and therefore cannot be conclusively stated. There is also no confirmed data in this context regarding the percentage stake represented by these shares in the company’s total equity base, so any precise change in shareholding of promoters, institutions, or funds must be treated as unknown for now. Similarly, immediate post-deal share price reaction or follow-through move in the stock is not detailed in the given input, so no inference on short-term price impact can be made without additional verifiable data.
In summary, the key takeaway is that Aarti Pharmalabs has seen a sizeable on-market block trade of Rs 62.93 crores on the NSE at Rs 821.9 per share for roughly 7.66 lakh shares, underscoring active interest from large market players while key details such as buyer or seller classification, stake change and post-trade price behaviour remain undisclosed in the current context.
Aarti Pharma reports higher first quarter EBITDA and margin expansion
ResultAARTIPHARM7 Aug 2026
Aarti Pharma reported first quarter EBITDA of Rs 136.00 crores, up from Rs 95.20 crores a year earlier, reflecting a year on year increase of about 42.8%.
EBITDA margin improved to 25.40% from 24.66% in the same period last year, indicating better operating efficiency and stronger profitability at the operating level. No revenue or profit after tax figure was provided in the available update, and no quarter on quarter comparison or street estimate was included.
The update is a routine quarterly operating result for the company and does not include management commentary, guidance, or market reaction in the provided text. The share-specific news flow is therefore limited to the reported EBITDA growth and margin improvement.
Aarti Pharma Q1 revenue rises to Rs 536 crores year on year
ResultAARTIPHARM7 Aug 2026
Aarti Pharma reported Q1 revenue of Rs 536.00 crores, compared with Rs 386.00 crores in the same period last year, reflecting a year on year increase of about 38.9%.
Only revenue was provided in the context, so EBITDA, PAT, and margin data are not available for this update. No consensus estimates, management commentary, or stock reaction were included in the input, so those items cannot be verified here.
Aarti Pharma reports Q1 standalone net profit rises to Rs 76.10 crores
ResultAARTIPHARM7 Aug 2026
Aarti Pharma reported Q1 standalone net profit of Rs 76.10 crores, compared with Rs 46.00 crores in the same quarter last year. The company provided only the net profit figure in the supplied update, so revenue, EBITDA, and margin details are not available from the context.
On a year-on-year basis, net profit increased by Rs 30.10 crores, reflecting a significant improvement in quarterly earnings. No quarter-on-quarter comparison, consensus estimate, management commentary, or market reaction was included in the provided text.
Aarti Pharmalabs reports lower Q4 profit, revenue rises year on year
ResultAARTIPHARM26 May 2026
Aarti Pharmalabs reported Q4 net profit of Rs 62.00 crores, compared with Rs 88.80 crores in the same quarter last year. Revenue for the quarter increased to Rs 580.00 crores from Rs 530.00 crores a year ago, indicating top-line growth despite weaker bottom-line performance.
No EBITDA, margin data, or management commentary was provided in the update. The available figures therefore indicate mixed quarterly performance, with higher revenue but lower net profit on a year-on-year basis.
Aarti Pharmalabs Q4 FY Earnings show weaker EBITDA and margin performance YoY
ResultAARTIPHARM26 May 2026
Aarti Pharmalabs reported a year-on-year decline in operating performance for the latest reported quarter, with both EBITDA and EBITDA margin softening compared with the same period last year. Quarterly EBITDA came in at Rs 117 crores versus Rs 140 crores in the year-ago quarter, indicating a contraction in operating profit levels on a YoY basis. The reduction in EBITDA suggests pressures either from softer revenue traction, higher operating costs, or an adverse product mix, though the specific revenue and PAT data points are not provided in the available disclosure.
EBITDA margin declined to 20.20 percent in the quarter from 26.56 percent in the corresponding quarter of the previous year, reflecting meaningful compression in operating profitability. This margin deterioration signals cost or pricing pressures and may point to challenges in passing on input cost inflation or maintaining earlier realizations. In the absence of reported revenue figures, PAT, or QoQ comparisons, the assessment is restricted to the visible deterioration in core operating metrics. No information is available in the provided context on management commentary, forward-looking guidance, or any one-off items that could have influenced the reported numbers.
Street expectations or consensus estimates are also not mentioned, so it is not possible to benchmark whether the reported EBITDA and margin were a beat, miss, or in line with market forecasts. Similarly, there is no data on immediate stock price reaction or trading volumes on NSE or BSE following the result announcement. Overall, the available figures indicate weaker operating performance on a YoY basis, driven by lower EBITDA and compressed margins, which investors and analysts would typically monitor closely for any sustained trend or signs of normalization in subsequent quarters.
Aarti Pharma Q4 EBITDA declines year-on-year with margin compression reported
ResultAARTIPHARM25 May 2026
Aarti Pharma reported a year-on-year decline in operating performance for the fourth quarter, as reflected in both absolute EBITDA and profitability ratios. Q4 EBITDA stood at Rs 110.00 crores versus Rs 140.00 crores in the same quarter last year, indicating a meaningful contraction in operating earnings on an annual comparison basis. This deterioration in EBITDA suggests either weaker operating leverage, adverse product mix, pricing pressure, higher input or operating costs, or a combination of these factors impacting the company during the quarter, though specific drivers are not disclosed in the available information.
In addition to the decline in absolute EBITDA, Aarti Pharma reported a sharp compression in its Q4 EBITDA margin. The Q4 EBITDA margin came in at 19.42 percent compared to 25.39 percent on a year-on-year basis, highlighting reduced operating efficiency and profitability per unit of revenue versus the prior-year quarter. The margin contraction of nearly 600 basis points indicates that cost pressures or lower realizations outpaced any revenue gains, or that scale benefits were weaker than in the corresponding period last year. There is no information available in the given context on revenue, PAT, or quarter-on-quarter trends, nor on management commentary, guidance, or market reaction. Street expectations, if any, are also not provided, so the extent of underperformance versus consensus cannot be quantified from the current data set.
Aarti Pharma Q4 profit declines sharply amid extraordinary revenue collapse YoY
ResultAARTIPHARM25 May 2026
Aarti Pharma reported a steep deterioration in its financial performance for the fourth quarter, led by an extraordinary collapse in reported revenue on a year-on-year basis. The company’s Q4 consolidated net profit came in at Rs 61.10 crores, down from Rs 88.30 crores in the corresponding quarter last year, indicating a significant contraction in profitability. This implies a notable decline in profit after tax on a YoY basis, reflecting weaker operating performance, adverse mix, or potential one-off impacts on margins, although detailed drivers and margin data are not available in the provided context.
On the top line, the reported Q4 revenue stood at only Rs 58.00 lakhs compared with Rs 564.00 crores in the same quarter a year ago, indicating an extremely sharp YoY decline in sales. Such a dramatic fall in revenue, if accurately reflected in statutory filings, would typically suggest either a major business restructuring, demerger, change in reporting classification, or the absence of earlier-period one-off revenue items. In the absence of further disclosures on segmental performance or management commentary, the precise reasons for this collapse in reported revenue cannot be ascertained from the given information. However, the combination of a near-wipeout in reported revenue and a substantial, though less severe, decline in net profit points to considerable pressure on the company’s operating environment and earnings quality in the quarter.
No data has been provided on EBITDA, operating margins, net margins, or quarter-on-quarter trends, and there is no reference to broker consensus or street expectations, so it is not possible to assess whether these results were above, in line with, or below market forecasts. Similarly, there is no information on management guidance, commentary on demand trends, input costs, or regulatory factors, and no details on immediate market reaction or stock price movement. Based solely on the reported YoY contraction in revenue and net profit, the earnings outcome appears incrementally negative for near-term sentiment around Aarti Pharma’s stock.
Aarti Pharmalabs reports Profit after tax of 62.03 Crores, in the March 2026 quarter
ResultAARTIPHARM25 May 2026
NULL
Aarti Pharmalabs informs about conference call
Stock NewsAARTIPHARM20 May 2026
NULL
Aarti Pharmalabs informs about analyst meet
Stock NewsAARTIPHARM20 May 2026
NULL
Aarti Pharmalabs informs about substantial acquisition of shares & takeovers
Stock NewsAARTIPHARM4 Apr 2026
NULL
Aarti Pharmalabs informs about disclosure
Stock NewsAARTIPHARM4 Apr 2026
NULL
Aarti Pharmalabs Receives One Procedural US FDA Form 483 Observation at Tarapur Unit-IV.
Stock NewsAARTIPHARM27 Mar 2026
Aarti Pharmalabs Limited's US FDA inspection at its Tarapur Unit-IV manufacturing facility in Maharashtra concluded on March 27, 2026, resulting in a single procedural Form 483 observation. The company has notified BSE and NSE under SEBI Regulation 30 and committed to submitting corrective and preventive actions (CAPA) within the stipulated timeframe. This procedural observation pertains to documentation or process compliance rather than product quality issues, allowing the facility to maintain operational status pending administrative corrections.
The development underscores ongoing regulatory scrutiny for Indian pharmaceutical exporters reliant on US FDA approvals. Aarti Pharmalabs, operating in the chemicals and pharma intermediates sector, has faced minor past regulatory matters, including a Rs 2.60 lakh CGST penalty in February 2026, but no severe outcomes like official action indicated or import alerts at this unit. Historical FDA inspections at Tarapur facilities date back to 2011, 2016, and 2020 with voluntary action indicated classifications, though unrelated to the current event.
No immediate stock price reaction or quantitative earnings impact is detailed in disclosures. The company's proactive CAPA response aligns with industry norms where single procedural observations typically do not disrupt exports or production.
The development underscores ongoing regulatory scrutiny for Indian pharmaceutical exporters reliant on US FDA approvals. Aarti Pharmalabs, operating in the chemicals and pharma intermediates sector, has faced minor past regulatory matters, including a Rs 2.60 lakh CGST penalty in February 2026, but no severe outcomes like official action indicated or import alerts at this unit. Historical FDA inspections at Tarapur facilities date back to 2011, 2016, and 2020 with voluntary action indicated classifications, though unrelated to the current event.
No immediate stock price reaction or quantitative earnings impact is detailed in disclosures. The company's proactive CAPA response aligns with industry norms where single procedural observations typically do not disrupt exports or production.
Aarti Pharmalabs informs about disclosures
Stock NewsAARTIPHARM24 Mar 2026
NULL
Aarti Pharmalabs Reports Minor Chemical Leak at Tarapur Unit-VI, 22 Workers Hospitalised, No Casualties.
Stock NewsAARTIPHARM24 Mar 2026
Aarti Pharmalabs Limited experienced a minor chemical leak at its Unit-VI in Tarapur, Palghar, Maharashtra, on March 22, 2026. The incident occurred around 1:45 PM during the filling of Di-Methyl Sulphate (DMS) into a tanker, when the chemical overflowed through the vent line, spilling a small quantity onto the ground.
The plant's safety team immediately shut the filling valve, evacuated nearby workers, and neutralised the spill using lime and soda ash, containing the situation by 2:30 PM. Fumes from the highly toxic DMS caused eye irritation and discomfort among workers involved in the response. As a precaution, 22 employees were sent to Lifeline Multispeciality Hospital for check-up around 7:00 PM. No serious injuries, casualties, or damage were reported, with symptoms limited to eye irritation and mild effects.
Operations at the unit resumed normalcy within 24 hours. This event adds to recent industrial incidents in Tarapur MIDC, including gas leaks at other facilities, prompting an ongoing investigation by authorities to ascertain causes and prevent recurrence.
Aarti Pharmalabs informs about transcript of earnings call
Stock NewsAARTIPHARM16 Feb 2026
NULL
Aarti Pharmalabs Q3 EBITDA Declines to Rs 102 Crores, Margin Slightly Down YoY.
ResultAARTIPHARM9 Feb 2026
Aarti Pharmalabs reported Q3 financial results with **EBITDA at Rs 102.00 crores**, down from Rs 129.00 crores YoY. **EBITDA margin** stood at **23.67%**, compared to 23.91% in the previous year.
Additional details from quarterly results indicate revenue at Rs 418.33 crores, reflecting a QoQ increase of 8.32% from Rs 386.19 crores and a YoY decline of 8.67%. Operating profit was Rs 8.39 crores, up 68.81% QoQ and 19.01% YoY. Net profit reported at Rs 49.50 crores, down 43.97% QoQ and 10.73% YoY. The company has scheduled an earnings conference call for February 10, 2026, to discuss Q3 FY26 results in detail with key management.

